346 related articles for article (PubMed ID: 21357783)
1. Results of the Intergroup Rhabdomyosarcoma Study Group D9602 protocol, using vincristine and dactinomycin with or without cyclophosphamide and radiation therapy, for newly diagnosed patients with low-risk embryonal rhabdomyosarcoma: a report from the Soft Tissue Sarcoma Committee of the Children's Oncology Group.
Raney RB; Walterhouse DO; Meza JL; Andrassy RJ; Breneman JC; Crist WM; Maurer HM; Meyer WH; Parham DM; Anderson JR
J Clin Oncol; 2011 Apr; 29(10):1312-8. PubMed ID: 21357783
[TBL] [Abstract][Full Text] [Related]
2. Shorter-duration therapy using vincristine, dactinomycin, and lower-dose cyclophosphamide with or without radiotherapy for patients with newly diagnosed low-risk rhabdomyosarcoma: a report from the Soft Tissue Sarcoma Committee of the Children's Oncology Group.
Walterhouse DO; Pappo AS; Meza JL; Breneman JC; Hayes-Jordan AA; Parham DM; Cripe TP; Anderson JR; Meyer WH; Hawkins DS
J Clin Oncol; 2014 Nov; 32(31):3547-52. PubMed ID: 25267746
[TBL] [Abstract][Full Text] [Related]
3. Reduction of cyclophosphamide dose for patients with subset 2 low-risk rhabdomyosarcoma is associated with an increased risk of recurrence: A report from the Soft Tissue Sarcoma Committee of the Children's Oncology Group.
Walterhouse DO; Pappo AS; Meza JL; Breneman JC; Hayes-Jordan A; Parham DM; Cripe TP; Anderson JR; Meyer WH; Hawkins DS
Cancer; 2017 Jun; 123(12):2368-2375. PubMed ID: 28211936
[TBL] [Abstract][Full Text] [Related]
4. Analysis of prognostic factors in patients with nonmetastatic rhabdomyosarcoma treated on intergroup rhabdomyosarcoma studies III and IV: the Children's Oncology Group.
Meza JL; Anderson J; Pappo AS; Meyer WH;
J Clin Oncol; 2006 Aug; 24(24):3844-51. PubMed ID: 16921036
[TBL] [Abstract][Full Text] [Related]
5. Benefit of intensified therapy for patients with local or regional embryonal rhabdomyosarcoma: results from the Intergroup Rhabdomyosarcoma Study IV.
Baker KS; Anderson JR; Link MP; Grier HE; Qualman SJ; Maurer HM; Breneman JC; Wiener ES; Crist WM
J Clin Oncol; 2000 Jun; 18(12):2427-34. PubMed ID: 10856103
[TBL] [Abstract][Full Text] [Related]
6. Which patients with microscopic disease and rhabdomyosarcoma experience relapse after therapy? A report from the soft tissue sarcoma committee of the children's oncology group.
Smith LM; Anderson JR; Qualman SJ; Crist WM; Paidas CN; Teot LA; Pappo AS; Link MP; Grier HE; Wiener ES; Breneman JC; Raney RB; Maurer HM; Donaldson SS
J Clin Oncol; 2001 Oct; 19(20):4058-64. PubMed ID: 11600608
[TBL] [Abstract][Full Text] [Related]
7. 45 Gy is not sufficient radiotherapy dose for Group III orbital embryonal rhabdomyosarcoma after less than complete response to 12 weeks of ARST0331 chemotherapy: A report from the Soft Tissue Sarcoma Committee of the Children's Oncology Group.
Ermoian RP; Breneman J; Walterhouse DO; Chi YY; Meza J; Anderson J; Hawkins DS; Hayes-Jordan AA; Parham DM; Yock TI; Donaldson SS; Wolden SL
Pediatr Blood Cancer; 2017 Sep; 64(9):. PubMed ID: 28548706
[TBL] [Abstract][Full Text] [Related]
8. Intergroup rhabdomyosarcoma study-IV: results for patients with nonmetastatic disease.
Crist WM; Anderson JR; Meza JL; Fryer C; Raney RB; Ruymann FB; Breneman J; Qualman SJ; Wiener E; Wharam M; Lobe T; Webber B; Maurer HM; Donaldson SS
J Clin Oncol; 2001 Jun; 19(12):3091-102. PubMed ID: 11408506
[TBL] [Abstract][Full Text] [Related]
9. Local control with reduced-dose radiotherapy for low-risk rhabdomyosarcoma: a report from the Children's Oncology Group D9602 study.
Breneman J; Meza J; Donaldson SS; Raney RB; Wolden S; Michalski J; Laurie F; Rodeberg DA; Meyer W; Walterhouse D; Hawkins DS
Int J Radiat Oncol Biol Phys; 2012 Jun; 83(2):720-6. PubMed ID: 22104356
[TBL] [Abstract][Full Text] [Related]
10. Embryonal rhabdomyosarcoma completely resected at diagnosis: The European paediatric Soft tissue sarcoma Study Group RMS2005 experience.
Bergeron C; Jenney M; De Corti F; Gallego S; Merks H; Glosli H; Ferrari A; Ranchère-Vince D; De Salvo GL; Zanetti I; Chisholm J; Minard-Colin V; Rogers T; Bisogno G;
Eur J Cancer; 2021 Mar; 146():21-29. PubMed ID: 33567392
[TBL] [Abstract][Full Text] [Related]
11. Local Control for Intermediate-Risk Rhabdomyosarcoma: Results From D9803 According to Histology, Group, Site, and Size: A Report From the Children's Oncology Group.
Wolden SL; Lyden ER; Arndt CA; Hawkins DS; Anderson JR; Rodeberg DA; Morris CD; Donaldson SS
Int J Radiat Oncol Biol Phys; 2015 Dec; 93(5):1071-6. PubMed ID: 26581144
[TBL] [Abstract][Full Text] [Related]
12. Vincristine, actinomycin, and cyclophosphamide compared with vincristine, actinomycin, and cyclophosphamide alternating with vincristine, topotecan, and cyclophosphamide for intermediate-risk rhabdomyosarcoma: children's oncology group study D9803.
Arndt CA; Stoner JA; Hawkins DS; Rodeberg DA; Hayes-Jordan AA; Paidas CN; Parham DM; Teot LA; Wharam MD; Breneman JC; Donaldson SS; Anderson JR; Meyer WH
J Clin Oncol; 2009 Nov; 27(31):5182-8. PubMed ID: 19770373
[TBL] [Abstract][Full Text] [Related]
13. Rhabdomyosarcoma and undifferentiated sarcoma in the first two decades of life: a selective review of intergroup rhabdomyosarcoma study group experience and rationale for Intergroup Rhabdomyosarcoma Study V.
Raney RB; Anderson JR; Barr FG; Donaldson SS; Pappo AS; Qualman SJ; Wiener ES; Maurer HM; Crist WM
J Pediatr Hematol Oncol; 2001 May; 23(4):215-20. PubMed ID: 11846299
[TBL] [Abstract][Full Text] [Related]
14. The Third Intergroup Rhabdomyosarcoma Study.
Crist W; Gehan EA; Ragab AH; Dickman PS; Donaldson SS; Fryer C; Hammond D; Hays DM; Herrmann J; Heyn R
J Clin Oncol; 1995 Mar; 13(3):610-30. PubMed ID: 7884423
[TBL] [Abstract][Full Text] [Related]
15. Ifosfamide and etoposide are superior to vincristine and melphalan for pediatric metastatic rhabdomyosarcoma when administered with irradiation and combination chemotherapy: a report from the Intergroup Rhabdomyosarcoma Study Group.
Breitfeld PP; Lyden E; Raney RB; Teot LA; Wharam M; Lobe T; Crist WM; Maurer HM; Donaldson SS; Ruymann FB
J Pediatr Hematol Oncol; 2001 May; 23(4):225-33. PubMed ID: 11846301
[TBL] [Abstract][Full Text] [Related]
16. Does debulking improve survival rate in advanced-stage retroperitoneal embryonal rhabdomyosarcoma?
Blakely ML; Lobe TE; Anderson JR; Donaldson SS; Andrassy RJ; Parham DM; Wharam MD; Qualman SJ; Wiener ES; Grier HE; Crist WM
J Pediatr Surg; 1999 May; 34(5):736-41; discussion 741-2. PubMed ID: 10359174
[TBL] [Abstract][Full Text] [Related]
17. The Intergroup Rhabdomyosarcoma Study-I. A final report.
Maurer HM; Beltangady M; Gehan EA; Crist W; Hammond D; Hays DM; Heyn R; Lawrence W; Newton W; Ortega J
Cancer; 1988 Jan; 61(2):209-20. PubMed ID: 3275486
[TBL] [Abstract][Full Text] [Related]
18. Volumetric considerations in radiotherapy for pediatric parameningeal rhabdomyosarcomas.
Chen C; Shu HK; Goldwein JW; Womer RB; Maity A
Int J Radiat Oncol Biol Phys; 2003 Apr; 55(5):1294-9. PubMed ID: 12654440
[TBL] [Abstract][Full Text] [Related]
19. Prognostic factors and surgical treatment guidelines for children with rhabdomyosarcoma of the perineum or anus: a report of Intergroup Rhabdomyosarcoma Studies I through IV, 1972 through 1997.
Blakely ML; Andrassy RJ; Raney RB; Anderson JR; Wiener ES; Rodeberg DA; Paidas CN; Lobe TE; Crist WM;
J Pediatr Surg; 2003 Mar; 38(3):347-53. PubMed ID: 12632347
[TBL] [Abstract][Full Text] [Related]
20. Outcome of patients with localized orbital sarcoma who relapsed following treatment on Intergroup Rhabdomyosarcoma Study Group (IRSG) Protocols-III and -IV, 1984-1997: a report from the Children's Oncology Group.
Raney B; Huh W; Hawkins D; Hayes-Jordan A; Million L; Rodeberg D; Teot L; Anderson J;
Pediatr Blood Cancer; 2013 Mar; 60(3):371-6. PubMed ID: 22961750
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]